May 22, 2023
Prometheus Biosciences, Inc. Investigation
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Prometheus Biosciences, Inc. (“Prometheus” or the “Company”) (NASDAQ: RXDX), in connection with its acquisition by Merck & Co., Inc. (NYSE: MRK). Under the merger agreement, Prometheus shareholders will receive $200.00 cash per share.
Join Case →